# A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1

> **NCT00824421** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 195 (actual)

## Conditions studied

- HIV-1

## Interventions

- **DRUG:** UK-453, 061
- **DRUG:** UK-453, 061
- **DRUG:** EFV +TVA

## Key facts

- **NCT ID:** NCT00824421
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2014-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00824421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00824421, "A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00824421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*